1. Home
  2. SKYE

as 05-22-2024 4:00pm EST

$
-
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

Founded: 2012 Country:
United States
United States
Employees: 11 City: SAN DIEGO
Market Cap: 337.1M IPO Year: N/A
Target Price: $22.50 AVG Volume (30 days): 53.6K
Analyst Decision: Buy Number of Analysts: 2
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -2.34 EPS Growth: N/A
52 Week Low/High: $1.44 - $19.41 Next Earning Date: 01-01-0001
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

Share on Social Networks:

Stock Insider Trading Activity of Skye Bioscience Inc. Common Stock (SKYE)

Name Ticker Relationship Date Transaction Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
5AM Partners VII, LLC SKYE 10% Owner Mar 13 '24 Buy $10.00 450,000 $4,500,000.00 8,393,520 SEC Form 4
5AM Partners VII, LLC SKYE 10% Owner Jan 31 '24 Buy $2.31 5,206,074 $12,026,030.94 7,943,520 SEC Form 4